Currently, sorafenib is the only systemic chemotherapy drug for advanced stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC patients indicate that sorafenib alone has only moderate antitumor efficacy, and could not inhibit disease metastasis and progression. | Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells